Monoclonal Gammopathy of Renal Significance (MGRS)



MGRS

• MGRS refers to kidney disease caused by nephrotoxic monoclonal immunoglobulins produced by a clonal B-cell or plasma cell disorder that does not meet criteria for hematologic malignancy but leads to kidney damage.



Why Does MGRS Matter?

• Occurs in patients with MGUS or smoldering myeloma/lymphoma.

• Leads to organ damage, especially kidneys.

• Historically underdiagnosed or misclassified as benign.

• If untreated, MGRS lesions can progress to end-stage kidney disease or evolve into hematologic malignancies.



Epidemiology:

• Present in 40–45% of patients with monoclonal gammopathy undergoing kidney biopsy.

• More common in older adults, especially males.



Clinical Clues:

• Nephrotic-range proteinuria or subnephrotic proteinuria with rapid decline in kidney function should raise suspicion for MGRS

• Proteinuria >1.5 g/day

• Hematuria

• Reduced kidney function

• Abnormal serum free light-chain ratio



Diagnostic Workup:

• Kidney biopsy is essential.

• Serum/urine protein electrophoresis (SPEP/UPEP)

• Immunofixation (SIFE/UIFE)

• Free light-chain assay

• Bone marrow biopsy

• Imaging and cytometry as needed for clone detection

• CT/PET imaging may be useful for extramedullary disease or lymphoproliferative clones

• Kidney biopsy findings guide subtype classification: organized (e.g., amyloid), non-organized (e.g., LCDD), or no deposits (e.g., C3GN)



Pathogenesis: How MGRS Damages Kidneys

• Low Tumor Burden, High Toxicity

• Mechanisms include:

   - Amyloid formation (e.g., AL amyloidosis)

   - Light-chain deposition disease (LCDD)

   - Crystal formation (e.g., light-chain proximal tubulopathy)

   - Complement pathway activation (e.g., C3 glomerulopathy)

   - Cryoglobulin formation causing vasculitis



Types of MGRS-Associated Lesions:

• Organized Deposits: AL amyloidosis, immunotactoid GN, cryoglobulinemic GN

• Non-organized Deposits: LCDD, PGNMID

• No Deposits: C3 glomerulopathy, thrombotic microangiopathy



Treatment Principles:

• Clone-directed therapy is key—not standard immunosuppressives.

• Plasma cell clone: Bortezomib, daratumumab

• B-cell clone (CD20+): Rituximab-based therapy

• Goal: Preserve kidney function and prevent progression.

• Transplant consideration: Only after achieving hematologic response.



#MGRS #Monoclonal #Gammopathy #Renal #Significance #Diagnosis